Fluorine 18 MK 6240

Drug Profile

Fluorine 18 MK 6240

Alternative Names: [18F]MK 6240; [18F]MNI-946; [F-18]MK-6240; Fluorine-18-MK6240; MK-6240

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Cerveau Technologies; Janssen Pharmaceuticals; Merck Sharp & Dohme; Washington University School of Medicine
  • Class Imaging agents; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Phase II Neurodegenerative disorders

Most Recent Events

  • 25 May 2018 Washington University School of Medicine suspends patient enrolment in the phase II/III DIAN-TU trial for Alzheimer's disease (Early-stage disease) in USA, United Kingdom, Spain and Italy to explore options to improve the benefit / risk for these patients (PO)
  • 15 May 2018 Cerveau Technologies signs agreement with Tokyo Metropolitan Institute of Gerontology for manufacture and supply of fluorine 18 MK 6240 for research studies in Japan
  • 05 Mar 2018 Phase-II clinical trials in Neurodegenerative disorders (Diagnosis, In volunteers) in USA (IV) (NCT03389100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top